BeOne Medicines (ONC) Stock Price, News & Analysis

Company Overview

BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.

Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers. BeOne also has a pipeline of investigational therapies designed to address additional hematologic and solid-tumor indications.

The company was founded in 2010 as BeiGene and adopted the BeOne Medicines name as part of its evolution into a global oncology-focused business. It serves patients and healthcare providers in China, the United States, Europe and other international markets. John V. Oyler, the company’s founder, serves as chief executive officer.

Key Stats

• Today's Range: $355.24 to $372.44
• 50-Day Range: $329.80 to $376.86
• 52-Week Range: $253.95 to $385.22
• Volume: 221,410 shs
• Average Volume: 306,055 shs
• Market Capitalization: $40.84 billion
• P/E Ratio: 65.49
• Dividend Yield: N/A
• Price Target: $404.93
• Consensus Rating: Buy

BeOne Medicines Stock Analysis - MarketRank™

BeOne Medicines scored higher than 75% of companies evaluated by MarketBeat, and ranked 117th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

BeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 13 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

BeOne Medicines has a consensus price target of $404.93, representing about 15.2% upside from its current price of $351.48.

Amount of Analyst Coverage

BeOne Medicines has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 52.28%

Earnings Growth

Earnings for BeOne Medicines are expected to grow by 52.28% in the coming year, from $8.99 to $13.69 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeOne Medicines is 61.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 36.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeOne Medicines is 61.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 223.62.

Price to Book Value per Share Ratio

BeOne Medicines has a P/B Ratio of 8.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.88% of the float of BeOne Medicines has been sold short.

Short Interest Ratio / Days to Cover

BeOne Medicines has a short interest ratio ("days to cover") of 4.96.

Change versus previous month

Short interest in BeOne Medicines has recently increased by 13.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeOne Medicines does not currently pay a dividend.

Dividend Growth

BeOne Medicines does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.36

News Sentiment

BeOne Medicines has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for BeOne Medicines this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

5 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $147,986,148.00 in company stock.

Percentage Held by Insiders

6.19% of the stock of BeOne Medicines is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ONC
• Previous Symbol: NASDAQ:ONC
• CIK: 1651308
• Web: beonemedicines.com
• Phone: 13459494123
• Fax: N/A
• Employees: 12,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BeOne Medicines: $404.93
• High Price Target: $459.00
• Low Price Target: $290.00
• Potential Upside/Downside: +8.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.68
• Trailing P/E Ratio: 65.49
• Forward P/E Ratio: 41.38
• P/E Growth: N/A
• Net Income: $286.93 million
• Net Margins: 10.70%
• Pretax Margin: 14.16%
• Return on Equity: 14.23%
• Return on Assets: 7.82%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 3.40
• Quick Ratio: 3.06

Sales & Book Value

• Annual Sales: $5.34 billion
• Price / Sales: 7.64
• Cash Flow: $4.17 per share
• Price / Cash Flow: 89.31
• Book Value: $39.77 per share
• Price / Book: 9.35

Miscellaneous

• Outstanding Shares: 109,790,000
• Free Float: 102,991,000
• Market Cap: $40.84 billion
• Optionable: N/A
• Beta: 0.61